作者:甘坛焕、方程嫣、姜铸轩、马居东、唐玉青摘要■投资逻辑研发能力突破,全球竞争力凸显。2025年全球医药投融资触底复苏,前11个月总额达1921亿美元,海内外市场同步改善,且呈现传统赛道稳健流入、ADC、双抗等新兴赛道加码的特征。全球及中国生物医药BD合作持续升温,交易数量与金额双升,中国创新药出海进入多品类攻坚阶段,License-out交易成为跨国交易主线。同时,中国创新药研发能力凸显,...
Source Link作者:甘坛焕、方程嫣、姜铸轩、马居东、唐玉青摘要■投资逻辑研发能力突破,全球竞争力凸显。2025年全球医药投融资触底复苏,前11个月总额达1921亿美元,海内外市场同步改善,且呈现传统赛道稳健流入、ADC、双抗等新兴赛道加码的特征。全球及中国生物医药BD合作持续升温,交易数量与金额双升,中国创新药出海进入多品类攻坚阶段,License-out交易成为跨国交易主线。同时,中国创新药研发能力凸显,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.